World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
Keywords: Epi Pen, Mylan, Drug Pricing, ,
The renewed debate on drug pricing after the EpiPen price increases by Mylan Pharmaceutical
08/26/2016
Grouped Articles
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Mylan Reacts to EpiPen Backlash
WSJ 08/26/2016
EpiPen Maker Dispenses Outsize Pay
WSJ 09/13/2016
Lawmakers grill Mylan CEO over EpiPen price hikes
Washington Post 09/22/2016
Mylan’s EpiPen Pretax Profits 60% Higher Than Number Told to Congress
WSJ 09/26/2016
Analysis | The Trump administration is taking on drug prices — but not drug companies
Washington Post 11/24/2017
Extremely high prices for some drugs in 2012-2016
07/25/2015
Grouped Articles
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
Washington Post 09/22/2015
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Mylan Reacts to EpiPen Backlash
WSJ 08/26/2016
Analysis | The Trump administration is taking on drug prices — but not drug companies
Washington Post 11/24/2017
How Pfizer set the price of new breast cancer drug Ibrance at $9850 a month in 2015
12/09/2015
Rockoff describes the little known ways pharmaceutical companies come up with prices of expensive drugs, using Ibrance as an example.
Grouped Articles
How Pfizer Set the Cost of Its New Drug at $9,850 a Month
Wall Street Journal 12/09/2015
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Mylan Reacts to EpiPen Backlash
WSJ 08/26/2016
Analysis | The Trump administration is taking on drug prices — but not drug companies
Washington Post 11/24/2017
Pricing of healthcare services and pharmaceuticals as the biggest problem in funding healthcare in the U.S.
01/31/2008
The cost of most healthcare services are double or higher in the U.S. than in Canada, Germany, France and Japan. By not bringing prices in line with the price in other major developed countries, the U.S. is effectively defunding infrastructure, R&D, education and other important means of improving competitiveness say experts. The methods of setting price present in these countries are notably absent in the U.S. The Obama healthcare bill and before that the Bush Medicare Prescription Drug Benefit simply leave this problem unaddressed.
Grouped Articles
Cuts Would Only Shift Health-Care Costs
Wall Street Journal 07/13/2011
Bayonne Medical Center Has Highest U.S. Billing Rates
New York Times 05/16/2013
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Washington Post 09/22/2015
Mylan strategies
06/15/2005
Grouped Articles
Mylan Proposes to Acquire Rival Perrigo for $28.9 Billion
Wall Street Journal 04/10/2015
Mylan Is Now Big Generics Player After Deal for Unit of Merck KGaA
Wall Street Journal 05/14/2007
Wall Street Journal 06/15/2005
Mylan Rejects Teva’s $40 Billion Takeover Offer
New York Times 04/27/2015
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Rapidly increasing prices of generic drugs 2013-2015
11/14/2014
Grouped Articles
Will Rising Prices for Some Generic Drugs Never End?
Wall Street Journal 11/14/2014
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Mylan Reacts to EpiPen Backlash
WSJ 08/26/2016
Analysis | The Trump administration is taking on drug prices — but not drug companies
Washington Post 11/24/2017
Turing Pharmaceuticals and the issue of exorbitant U.S. drug pricing in 2015
09/22/2015
Grouped Articles
Washington Post 09/22/2015
‘Pharma Bro’ Martin Shkreli arrested for securities fraud - The Washington Post
Washington Post 12/17/2015
Painted as EpiPen Villain, Mylan’s Chief Says She’s No Such Thing
The New York Times 08/26/2016
Mylan Reacts to EpiPen Backlash
WSJ 08/26/2016
Analysis | The Trump administration is taking on drug prices — but not drug companies
Washington Post 11/24/2017
Meeting the cost concerns of governments and insurers. Efforts by pharmaceutical companies.
11/09/2006
Efforts by companies like GlaxoSMithKline to meet cost concerns of governments by linking pricing to the effectiveness of the drugs or treatments. Pharmaceutical pricing an issue with governments.
Grouped Articles
Wall Street Journal 11/09/2006
Glaxo Chief Charts New Growth Strategy
Wall Street Journal 06/10/2008
Pricey Drugs Put Squeeze on Doctors
Wall Street Journal 07/08/2008
Drug Makers Trim Prices for Health Overhaul
Wall Street Journal 06/22/2009
For Drug Makers, Concessions Have a Bright Side
Wall Street Journal 06/23/2009
New York Times 06/25/2009
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us